Evaluation of the safety and utility of the Radiofrequency Vapor Ablation (RFVA) system for duodenal mucosal ablation in a porcine model: a novel therapeutic strategy for type 2 diabetes (T2D)

Aims Duodenal mucosal ablation (DA) is a promising endoscopic treatment for metabolic disease including T2D. A multitude of technologies are in development; however, limitations exist around usability, ablation uniformity, and adverse events. Vapor ablation, using the FDA cleared Aqua Medical RFVA system, is an emerging therapy that could be used for DA. Proof-of-concept data in Barrett's esophagus has established its safety and technical feasibility [1]. We aimed to evaluate the safety and utility of RFVA in the duodenum in a porcine dosimetry pre-clinical study.